Richard William Harbron

Richard William Harbron

Auto-generated profile, based on publicly available information

Richard William Harbron

Population Health Sciences Institute, Newcastle University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in British Journal of Cancer
Verified
Journal Article
Open access
AGAmy Berrington de Gonzalez
Amy Berrington de Gonzalez
JSJane A Salotti
Jane A Salotti
KMKieran McHugh
Kieran McHugh
MLMark P Little
Mark P Little
RHRichard W Harbron
Richard W Harbron
MPMark S Pearce
Mark S Pearce
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

8 November 2016 in British Journal of Cancer
Verified
Journal Article
Open access
NJNeige M.Y. Journy
Neige M.Y. Journy
CLChoonsik Lee
Choonsik Lee
RHRichard W Harbron
Richard W Harbron
KMKieran McHugh
Kieran McHugh
MPMark S Pearce
Mark S Pearce
AGAmy Berrington de González
Amy Berrington de González
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

18 August 2016 in Heart
Verified
Journal Article
Open access
PDF file
RHRichard W Harbron
Richard W Harbron
CCClaire-Louise Chapple
Claire-Louise Chapple
JOJohn J O'SUllivan
John J O'SUllivan
KBKate E Best
Kate E Best
AGAmy Berrington de González
Amy Berrington de González
MPMark S Pearce
Mark S Pearce
Objectives To estimate the risk of developing cancer in relation to the typical radiation doses received from a range of X-ray guided cardiac catheterisations in children, taking variable survival into account. Methods Radiation doses were estimated for 2749 procedures undertaken at five UK hospitals using Monte Carlo simulations. The lifetime attributable risk (LAR) of cancer incidence was estimated using models developed by the Biological Effects of Ionising Radiation committee, based on both normal life expectancy, and as a function of attained age, from 20 to 80 years, to take reduced life expectancy into account. Results The radiation-related risks from these procedures are dominated by lung and breast cancer (for females). Assuming normal life expectancy, central LAR estimates for cancer incidence, based on median doses, ranged from <1 in 2000 for atrial septal defect occlusions to as high as 1 in 150 for valve replacements. For a reduced life expectancy of 50 years, estimated risks are lower by a factor of around 7. For conditions with especially poor survival (age 20 years), such as hypoplastic left heart syndrome, estimated cancer risks attributable to radiation were <1 in 20 000. Conclusions Based on recent UK radiation dose levels, the risk of cancer following cardiac catheterisations is relatively low and strongly modified by survival and the type of procedure. The risk of breast cancer, especially following pulmonary artery angioplasty and valve replacements, is the greatest concern.

28 November 2016 in Journal of Radiological Protection
Verified
Journal Article
Closed access
PDF file
RHR W Harbron
R W Harbron
SDS Dreuil
S Dreuil
MBM-O Bernier
M-O Bernier
MPM S Pearce
M S Pearce
ITIsabelle Thierry-Chef
Isabelle Thierry-Chef
HBH Baysson
H Baysson
A large number of investigations into the radiation doses from x-ray guided interventional cardiology procedures in children have been carried out in recent years. A review was conducted of these studies, gathering data on kerma area product (P KA), fluoroscopic screening time (FT), air kerma, and estimates of effective dose and organ doses. The majority of studies focus on P KA and FT with no estimation of dose to the patient. A greater than ten-fold variation in average P KA was found between different studies, even where data were stratified by patient age or weight. Typical values of P KA were 0.6–10 Gy cm2 (<1 year/10 kg), 1.5–30 Gy cm2 (1–5 years), 2–40 Gy cm2 (5–10 years), 5–100 Gy cm2 (10–16 years) and 10–200 Gy cm2 (>16 years). P KA was lowest for heart biopsy (0.3–10 Gy cm2 for all ages combined) and atrial septostomy (0.4–4.0 Gy cm2), and highest for pulmonary artery angioplasty (1.5–35 Gy cm2) and right ventricular outflow tract dilatation (139 Gy cm2). Most estimates of patient dose were in the form of effective dose (typically 3–15 mSv) which is of limited usefulness in individualised risk assessment. Few studies estimated organ doses. Despite advances in radiation protection, recent publications have reported surprisingly large doses, as represented by P KA and air kerma. There is little indication of a fall in these dose indicators over the last 15 years. Nor is there much suggestion of a fall in doses associated with the use of flat panel detectors, as opposed to image intensifiers. An assessment of the impact of radiation dose in the context of overall patient outcome is required.

1 April 2015 in British Journal of Radiology
Verified
Journal Article
Closed access
RHR W Harbron
R W Harbron
MPM S Pearce
M S Pearce
JSJ A Salotti
J A Salotti
KMK McHugh
K McHugh
CMC McLaren
C McLaren
CCC-L Chapple
C-L Chapple
Objective:To gather data on radiation doses from fluoroscopically guided cardiac catheterization procedures in patients aged under 22 years at multiple centres and over a prolonged period in the UK. To evaluate and explain variation in doses. To estimate patient-specific organ doses and allow for possible future epidemiological analysis of associated cancer risks.Methods:Patient-specific data including kerma area product and screening times from 10,257 procedures carried out on 7726 patients at 3 UK hospitals from 1994 until 2013 were collected. Organ doses were estimated from these data using a dedicated dosimetry system based on Monte Carlo computer simulations.Results:Radiation doses from these procedures have fallen significantly over the past two decades. The organs receiving the highest doses per procedure were the lungs (median across whole cohort, 20.5 mSv), heart (19.7 mSv) and breasts (13.1 mSv). Median cumulative doses, taking into account multiple procedures, were 23.2, 22.2 and 16.7 mSv for t...

18 January 2018 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
RHRichard W. Harbron
Richard W. Harbron
CCClaire-Louise Chapple
Claire-Louise Chapple
JOJohn J. O’sUllivan
John J. O’sUllivan
CLChoonsik Lee
Choonsik Lee
KMKieran McHugh
Kieran McHugh
MPMark S. Pearce
Mark S. Pearce
Children and young adults with heart disease appear to be at increased risk of developing cancer, although the reasons for this are unclear. A cohort of 11,270 individuals, who underwent cardiac catheterizations while aged ≤ 22 years in the UK, was established from hospital records. Radiation doses from cardiac catheterizations and CT scans were estimated. The cohort was matched with the NHS Central Register and NHS Transplant Registry to determine cancer incidence and transplantation status. Standardized incidence ratios (SIR) with associated confidence intervals (CI) were calculated. The excess relative risk (ERR) of lymphohaematopoietic neoplasia was also calculated using Poisson regression. The SIR was raised for all malignancies (2.32, 95% CI 1.65, 3.17), lymphoma (8.34, 95% CI 5.22, 12.61) and leukaemia (2.11, 95% CI 0.82, 4.42). After censoring transplant recipients, post-transplant, the SIR was reduced to 0.90 (95% CI 0.49, 1.49) for all malignancies. All lymphomas developed post-transplant. The SIR for all malignancies developing 5 years from the first cardiac catheterization (2 years for leukaemia/lymphoma) remained raised (3.01, 95% CI 2.09, 4.19) but was again reduced after censoring transplant recipients (0.98, 95% CI 0.48, 1.77). The ERR per mGy bone marrow dose for lymphohaematopoietic neoplasia was reduced from 0.541 (95% CI 0.104, 1.807) to 0.018 (95% CI − 0.002, 0.096) where transplantation status was accounted for as a time-dependent background risk factor. In conclusion, transplantation appears to be a large contributor to elevated cancer rates in this patient group. This is likely to be mainly due to associated immunosuppression, however, radiation exposure may also be a contributing factor.